Onxeo announces its financial calendar for 2016

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, today announces its financial calendar for 2016:

February 26, 2016     Full-year 2015 results
April 6, 2016         General shareholders’ meeting (to be convened in Paris)
April 28, 2016        Quarterly information as of March 31, 2016
July 28, 2016         Consolidated accounts for the 1st half of 2016
October 25, 2016      Quarterly information as of September 30, 2016

This financial calendar is for indicative purposes only and Onxeo could change
its publication dates should it deem it necessary.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™)
Validive® (Clonidine Lauriad®)
Beleodaq® (belinostat)

For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51244254&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=d81488c4cf5b0cd62bc8a34b4883ebcc)

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51244254&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=005905a10
7 
730ddb65ce154ec9a210e1)

Follow us on Twitter @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51244254&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=d997b2d2942e3a754035b83a44adeba9)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51244254&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=a405a1130aa588b0384f637eab24a2dc)).
Investor Relations, Onxeo
Nathalie Delair-Trepo, +33 1 45 58 76 00
investors@onxeo.com
or
Alize RP (France)
Caroline Carmagnol / Florence Portejoie, +33 6 64 18 99 59 / +33 1 44 54 36 64
onxeo@alizerp.com
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1-508-280-6592 / +1-646-536-7012
kthomas@theruthgroup.com / lroth@theruthgroup.com